Journals / Turkish Journal of Gastroenterology / 2015 / Cilt: 26 - Sayı: 6

Cystic fluid chromogranin A levels in different pancreatic cystic lesions

Pages
522–527
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

It also has no value in the differential diagnosis of other pancreatic cysts

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Background/Aims: Pancreatic cystic lesions have a broad spectrum of differential diagnosis.
📊
Key Findings & Data:Cytopathological analysis and biochemical analysis, including cystic fluid carcinoembryonic antigen (CEA), amylase, Ca 19-9, and CgA, were performed.
💡
Conclusion & Impact:It also has no value in the differential diagnosis of other pancreatic cysts
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Özet

Background/Aims: Pancreatic cystic lesions have a broad spectrum of differential diagnosis. There is an ongoing demand to identify specific and sensitive cystic fluid markers for the differential diagnosis of pancreatic cysts. We aimed to evaluate the diagnostic value of cystic fluid chromogranin A (CgA) in the differential diagnosis of pancreatic cysts. Materials and Methods: Patients who underwent endoscopic ultrasound (EUS)-guided aspiration for pancreatic cysts were included in the study. Cytopathological analysis and biochemical analysis, including cystic fluid carcinoembryonic antigen (CEA), amylase, Ca 19-9, and CgA, were performed. Results: Fifty-three patients were included in the study. The final diagnosis of patients was 14 pancreatic pseudocysts, 10 intraductal papillary mucinous neoplasms (IPMNs), 8 mucinous cystic neoplasms (MCN), 8 serous cystadenomas (SCAs), 2 cystic pancreatic neuroendocrine tumors (PNETs), and 11 others. The mean CgA levels were 50.51±130.04 ng/mL in pseudocysts, 12.38±8.59 in MCN, and 13.76±10.90 in cystic PNET. There was only one patient with a very high cystic fluid CgA (515.49 ng/mL) and was diagnosed as pseudocyst developed in chronic pancreatitis patient. Two patients with cystic PNET had normal levels of cystic fluid CgA. Conclusion: Cystic fluid CgA is not a useful marker for the differential diagnosis of cystic PNETs. It also has no value in the differential diagnosis of other pancreatic cysts

🔖

Cite This Article

ORUÇ, N., AYDIN, A., BARUTÇUOĞLU, B., AKTAN, .., NART, D., VERAL, A. (2015). Cystic fluid chromogranin A levels in different pancreatic cystic lesions. Turkish Journal of Gastroenterology, Cilt: 26 - Sayı: 6, 522–527. https://ajindex.com/articles/409455

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (1)

  1. Dudeja V, Allen PJ. Premalignant cystic neoplasms of the pancreas. Semin Oncol 2015; 42: 70-85. [CrossRef] 2. Thiruvengadam N, Park WG. Systematic Review of Pancreatic Cyst Fluid Biomarkers: The Path Forward. Clin Transl Gastroenterol 2015; 11; 6: e88. 3. Lee LS. Diagnostic approach to pancreatic cysts. Curr Opin Gastroenterol 2014; 30: 511-7. [CrossRef] 4. Nakai Y, Isayama H, Itoi T, et al. Role of endoscopic ultrasonography in pancreatic cystic neoplasms: where do we stand and where will we go? Dig Endosc 2014; 26: 135-43. [CrossRef] 5. Clores MJ, Thosani A, Buscaglia JM. Multidisciplinary diagnostic and therapeutic approaches to pancreatic cystic lesions. J Multidiscip Healthc 2014; 3: 81-91. 6. Vinik AI. Advances in diagnosis and treatment of pancreatic neuroendocrine tumors. Endocr Pract 2014; 20: 1222-30. [CrossRef] 7. D’amico MA, Ghinassi B, Izzicupo P, Manzoli L, Di Baldassarre A. Biological function and clinical relevance of chromogranin A and derived peptides. Endocr Connect 2014; 3: R45-54. [CrossRef] 8. Corti A, Ferrero E. Chromogranin A and the endothelial barrier function. Curr Med Chem 2012; 19: 4051-8. [CrossRef] 9. Wu PB, Deng YZ, Shu YX, Tan SY, Li M, Fang G. Increased plasma CgA levels associated with nonalcoholic fatty liver disease. Turk J Gastroenterol 2015. 10. Adsay NV. Cystic neoplasia of the pancreas: pathology and biology J. Gastrointest Surg 2008; 12: 401-4. [CrossRef] 11. Yoon WJ, Daglilar ES, Pitman MB, Brugge WR. Cystic pancreatic neuroendocrine tumors: endoscopic ultrasound and fine-needle aspiration characteristics. Endoscopy 2013; 45: 189-94. [CrossRef] 12. Vege SS, Ziring B, Jain R, Moayyedi P. Clinical Guidelines Committee; American Gastroenterology Association. American gastroenterological association institute guideline on the diagnosis and management of asymptomatic neoplastic pancreatic cysts. Gastroenterology 2015; 148: 819-22. [CrossRef] 13. Hol L, Signoretti M, Poley JW. Management of pancreatic cysts: a review of the current guidelines. Minerva Gastroenterol Dietol 2015; 61: 87-99. 14. Sugimoto M, Takagi T, Hikichi T, et al. Efficacy of endoscopic ultrasonography-guided fine needle aspiration for pancreatic neuroendocrine tumor grading. World J Gastroenterol 2015; 21: 8118-24. 15. Caglià P, Cannizzaro MT, Tracia A, et al. Cystic pancreatic neuroendocrine tumors: To date a diagnostic challenge. Int J Surg 2015; Suppl 1:1S44-9. 16. Kongkam P, Al-Haddad M, Attasaranya S, et al. EUS and clinical characteristics of